hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma.

Abstract

Purpose: Circular RNA (circRNA) is a key regulatory factor in the development and progression of human tumors. However, the working mechanism and clinical significance of most circRNAs remain unknown in human cancers, including multiple myeloma (MM). Patients and Methods: This study employs high-throughput circRNA microarray with bioinformatics to identify differentially expressed circRNAs in patients with MM. The hsa_circ_0007841 expressions were observed in the MM tissues of 86 patients. Drug-resistant cell lines and pathological features were also detected. In addition, the relationship between hsa_circ_0007841 expressions in the MM tissues and the pathological features of patients with MM were evaluated and role of hsa_circ_0007841 as a potential biomarker and therapeutic target was assessed. Results: The results show that in the MM cell lines and drug-resistant cell lines, hsa_circ_0007841 expression was significantly upregulated, which was closely associated with disease prognosis. Specifically, hsa_circ_0007841 upregulation was correlated with chromosomal aberrations such as gain 1q21, t (4:14) and mutations in ATR and IRF4 genes. This finding was corroborated in large samples. Finally, bioinformatics analysis showed that eight differentially expressed miRNAs and 10 candidate mRNAs interacted with hsa_circ_0007841, shedding some new light on the basic functional research. Conclusion: This study may be the first to report that hsa_circ_0007841 is significantly upregulated in MM. It also suggests that hsa_circ_0007841 may be a novel biomarker for MM and its involvement in the progression of MM.

• Authors: Meng Gao, Chengyuan Li, Han Xiao, Hang Dong, Siyi Jiang, Yunfeng Fu, Liying Gong
• Journal: Frontiers in oncology (Front Oncol) Vol. 9 Pg. 1261 ( 2019) ISSN: 2234-943X [Print] Switzerland
• PMID: 31803627 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Gao, Li, Xiao, Dong, Jiang, Fu and Gong.